drug-discovery

Today in AI for life science: AI drug discovery hits its reckoning year — billions committed, zero approvals — tougher economics reshape the field, and the human cell reference map matures underneath it all.

Today in AI for life science: multi-agent ‘AI co-scientists’ land in Nature with real biomedical targets, an AI agent takes over the cryo-EM pipeline and finds a new structural state, and validation stays the moat.

Today in AI for life science: an AI system that autonomously discovers and validates a drug candidate, frontier labs buying into biology, a clear-eyed benchmark of cell-segmentation foundation models, and the case for composable multimodal models.